ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas2026
Nicotinamide mononucleotide alleviates the streptozotocin-mediated ferroptosis of islet β-cells via the Nrf2/GPX4 pathway.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of nicotinamide mononucleotide (NMN) on streptozotocin (STZ)-induced islet β-cell dysfunction and the underlying mechanisms have not been fully elucidated. This study investigated the ameliorative effect and mechanism of NMN on islet β-cell dysfunction. NMN significantly increased the INS-1 cell viability following treatment with either STZ or erastin and effectively mitigated STZ-induced cell injury. Upon exposure to STZ, INS-1 cells exhibited significantly elevated intracellular Fe2+ levels, significantly increased reactive oxygen species (ROS) levels, and significantly decreased in the activities of superoxide dismutase (SOD) and glutathione (GSH). The levels of lipid peroxidation (LPO) and malondialdehyde (MDA) were substantially increased, and the mitochondrial membrane potential significantly decreased. Transmission electron microscopy further revealed mitochondrial shrinkage, rupture of the mitochondrial membrane, and disintegration of mitochondrial cristae. NMN markedly reduced intracellular iron accumulation in INS-1 cells treated with STZ. NMN subsequently attenuated intracellular ROS, LPO, and MDA levels while restoring GSH and SOD activities in STZ-exposed cells. Moreover, NMN restored the mitochondrial membrane potential and reversed the STZ-induced pathological changes in mitochondrial morphology. Compared with STZ treatment, ferrostatin-1 treatment significantly upregulated Nrf2 and GPX4 expression. In contrast, compared with STZ treatment, erastin treatment suppressed Nrf2 and GPX4 expression. Notably, compared with STZ or erastin treatment, cotreatment with NMN resulted in a further reduction in Keap1 expression and a significant upregulation of Nrf2 and GPX4. NMN may alleviate STZ-induced INS-1 cell ferroptosis by activating the Nrf2/GPX4 pathway, providing a theoretical basis for the treatment of diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.